Optima: Optimizing Prograf Therapy in Maintenance Allografts II — OPTIMAII  

Kidney Transplantation Clinical Trial

Official title: Optima: Optimizing Prograf Therapy in Maintenance Allografts II

Status Completed

Clinical Trial Summary

This study is designed to optimize calcineurin immunosuppressive regimens and evaluate immunological and non-immunological markers that may explain mechanistic differences in these agents and their effects.

Clinical Trial Description

One of the major challenges in transplantation over the past two decades has been managing long-term renal function. Serum creatinine is the most commonly used serum marker of renal function. However serum creatinine is insensitive for detecting small decreases in glomerular filtration rate (GFR). Another marker for renal function is cystatin C. Dharnidharka et al concluded that cystatin C is superior to serum creatinine as a marker of kidney function since cystatin C was a more sensitive marker than serum creatinine for detecting decreases in GFR. Pirsch et al reported that tacrolimus-treated patients had a lower incidence of severe acute rejection and better lipid profiles than cyclosporine-treated patients.

Cardiovascular disease is the primary cause of premature death in renal and other transplant recipients. Current immunosuppressive protocols often elevate cardiovascular disease risk factors such as hypertension, hyperlipidemia, obesity and diabetes.

This study is designed to optimize calcineurin immunosuppressive regimens to ensure the best possible long-term outcomes after renal transplantation. ;

Related Conditions & MeSH terms

• Kidney Transplantation

• NCT number: NCT00905515
• Study type: Interventional
• Source: East Carolina University
• Status: Completed
• Phase: Phase 4
• Start date: August 2003
• Completion date: July 2008